<DOC>
	<DOCNO>NCT00996216</DOCNO>
	<brief_summary>The purpose study test safety tolerability eltrombopag use increase maintain platelet count . Platelet count maintain level sufficient facilitate initiation antiviral therapy , minimize antiviral therapy dose reduction , avoid permanent discontinuation antiviral therapy .</brief_summary>
	<brief_title>Clinical Trial Non-responders Who Previously Participated Eltrombopag Studies TPL 103922 TPL 108390</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Prior participation protocol TPL103922 TPL108390 complete Week 24 Follow Up Visit TPL103922 TPL108390 Male female â‰¥18 year old Evidence chronic HCV infection While participate TPL103922 TPL108390 , discontinue study drug due thrombocytopenia Appropriate candidate antiviral therapy pegylated interferon plus ribavirin Platelet count &lt; 75,000 Fertile male female must use two form effective contraception treatment 24 week treatment Ability understand comply protocol requirement instruction Ability provide write informed consent Decompensated liver disease Known hypersensitivity , intolerance , allergy interferon , ribavirin , eltrombopag , ingredient History clinically significant bleed oesophageal gastric varix History arterial venous thrombosis two follow risk factor : hereditary thrombophilic disorder ; hormone replacement therapy ; systemic contraception ( contain estrogen ) ; smoke ; diabetes ; hypercholesterolemia ; medication hypertension cancer Preexisting cardiac disease ( congestive heart failure Grade III/IV ) arrhythmias know involve risk thromboembolic event ( e.g . atrial fibrillation ) Evidence hepatocellular carcinoma HIV Hepatitis B infection Therapy antineoplastic immunomodulatory treatment within six month prior eltrombopag therapy Malignancy diagnose treat within past five year . Except localized basal squamous cell carcinoma treat local excision malignancy adequately treat , opinion oncologist , excellent chance cancerfree survival . Pregnant nursing woman Men female partner pregnant History alcohol/drug abuse dependence within six month study start unless participate control rehabilitation programme . Treatment investigational drug interferon within 30 day 5 halflives ( whichever longer ) screen visit History platelet clump prevents reliable measurement platelet count Evidence portal vein thrombosis within three month baseline visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Peginterferon</keyword>
	<keyword>Platelets</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Hepatitis C-related thrombocytopenia</keyword>
	<keyword>Thrombocytopenia</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Thrombopoietin</keyword>
</DOC>